September 7, 2021 7:51am
Some think by climbing through a mirror into the world that can see beyond; that the market is just a reflection, where everything is reversed, including logic
A holiday session short week with Rosh Hashanah (Jewish New Year) = low volume, high volatility?
Pre-open indications: SELLs: 2; SELL into Strength: 1; BUY: 5; Maintain SELL: 1
News: Alnylam Pharmaceuticals (ALNY (pre-market +$3.08), announced additional positive results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3 study of vutrisiran <read more>
If you’re looking for sector intel, ideas and facts or Insight in a volatile climate, RMi defines the extenuating factors of share pricing.
Never leave an investor uninformed!
Dow futures are UP +0.10% (+36 points), S&P futures are UP +0.06% (+3 point) and NASDAQ futures are DOWN -0.02% (-3 point)
U.S. stock futures fluctuated mixed early Tuesday morning,
European stocks were muted with lackluster sentiment,
Asia-Pacific stocks were mixed, as data showed China’s August trade data came in above expectations.
In trading Friday, the Dow lost 74.73 points, or 0.21%, the S&P 500 fell slightly by 0.03%; while the Nasdaq rose 0.21%, before the three-day Labor Day weekend.
One week into September, the major averages are all up, despite a muted kickoff to for the month. Year-to-date, the Dow is up 15.5%, the S&P is up 20.7% and the Nasdaq Composite is up 19.2%, although investors and analysts are still on the lookout for a major correction in September. <CNBC>
Today’s sector news:
Alnylam Pharmaceuticals (ALNY), announced additional positive results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3 study of vutrisiran, an investigational RNAi therapeutic in development for the treatment of transthyretin-mediated (ATTR) amyloidosis.
- Data presented at the 3rd European ATTR Amyloidosis Meeting further supports and builds on the previously reported primary and secondary endpoint results of the HELIOS-A study in hereditary ATTR amyloidosis patients with polyneuropathy, with improvements observed across important areas of patient health and function, including neuropathy impairment,
- Quality of Life (QoL), ability to perform daily activities and social engagement, nutritional status, and cardiac stress.
If you didn’t remember what happen at Friday night’s close and the quarter’s “number’s” impact, you won’t be prepared for today’s session:
- Friday’s evening’s recap: “the cell and gene therapy highs hit the wall and bounced to the downside” … https://www.regmedinvestors.com/articles/12080
- Monday’s message: Happy Labor Day … https://www.regmedinvestors.com/articles/12081
- The Nasdaq closed UP +32.34 (+0.21%) points,
- The IBB closed down -0.11% and XBI closed down -1.41%,
- Sector volume was LOW with 1 of the 8-upside having higher than the 3-month average volume with very LOW volume of 2 of -downside having higher than the 3-month average volume;
- The CBOE Volatility Index (VVIX: INDEX) Friday was flat at 0.00 points or 0.00% at 16.41,
- Friday’s percentage (%) of the 8-upside were +0.69% (RGNX) to +12.54% (BSTG) while the 26-downside -0.58% (QURE) to -7.51% (ADVM);
- September, 2 positive and 1 negative close
- August - 12 positive and 10 negative close
- July: 6 positives, 1 holiday and 15 negative closes
Q2/21 Earnings releases … https://www.regmedinvestors.com/articles/11542 … to date:
Companies in my headlights – It’s your decision; I provide an idea and context:
The Biostage (BSTG) Chronicles - Maintaining Sell – notice how the shares trade with the “pump/promote”?
Biostage (BSTG) closed up on Friday +$0.39 to $3.50 with 980 shares traded after Thursday’s +$0.11 with 14,339 shares traded, Wednesday’s -$0.36 to $3.00 and last Tuesday’s -$0.44 to $3.36 with 11,564 shares traded following the previous Monday’s +$0.75 to $3.80 with 25,607 shares traded,
The previous week’s Friday’s +$0.45 to $3.05 with 19,982 share traded, Thursday’s +$0.39 with 3,137 shares traded, Wednesday’s +$0.16 with 18,472 shares traded following Tuesday’s +$0.28 with 10,590 shares traded and the former and previous Monday’s +$0.68 to $1.89 with 38,354 shares traded.
Question#1: Being able to trade a stock doesn't mean it is worth the share price; an equity that has WHAT is BSTG’s value proposition, after all the share price pumping – NO clinical trial?
Questiob#2: WHAT is the end game of “pumping” the share price as the float is MINIMAL compared to the ever-OUTSTANDING shares? WHERE is the SEC?
MINORITY PUBLIC shareholders are waiting for the specific time, watching and weighing responses to MAINTAIN their RIGHTS.
Pre-open Indications: who’s lookin’ which way …
Pluristem (PSTI) closed up +$0.12 to $3.17 and has no pre-market indication with a 52-week high of $11.85 and low of $2.81,
ReNeuron (RENE.L) closed up +$4.00 (on Friday) and is bouncing down -$1.84 on Tuesday,
SELL into Strength:
Intellia Therapeutics (NTLA) closed up again +$2.77 to $176.78 after Thursday’s +$9.97, Wednesday’s +$4.51, last Tuesday’s+$6.58 and the previous Monday’s down -$6.05 with a positive +$0.60 or +0.34% pre-market indication,
BUY – potentials based on the pre-market:
Alnylam Pharmaceuticals (ALNY) closed down -$2.72 to $197.46 and has a positive +$3.08 or +1.56% pre-market indication based on announcing additional positive results from subgroup analyses and exploratory endpoints of the HELIOS-A Phase 3 study of vutrisiran,
bluebird bio (BLUE) closed down -$0.40 to $18.00 and has a positive +$0.23 or +1.28% premarket indication,
Cellectis SA (CLLS) closed down -$0.09 to $15.24 after Thursday’s up +$0.41 and has a positive +$0.14 or +0.92% pre-market indication,
CRISPR Therapeutics (CRSP) closed down -$5.11 to $121.96 and has a positive +$1.14 or +0.93% pre-market indication,
Editas Medicine (EDIT) closed down -$4.69 and has a positive +$2.12 or +3.11% pre-market indication,
The BOTTOM LINE: Investors will be keeping an eye on sector sentiment on Tuesday after markets there were closed on Monday for a holiday. U.S. stock futures were fractionally higher in early pre-market trade after the Nasdaq popped to another record high on Friday.
The setup for stem, cell and gene therapy sector equities is a unique universe and is showing a lot of resilience in the face of some waning economic data and the lack of new clinical date releases.
When you’re on a roller coaster, the only thing you can be sure of is you’ll end up back where you started
Investors should take short-term profits to cash-up for coming drifts!
Some earnings’ Reports Outstanding:
- Applied Genetic Technologies (AGTC) – 9/8 reporting, Mesoblast (MESO) – still trying to access, Pluristem (PSTI) and ReNeuron (RENE.L)
RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.